Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed)
ID: 352010Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352010

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-003.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Approaches for Radiation Biodosimetry Assays and Devices Development," aimed at advancing research in radiation exposure assessment. This initiative seeks to support the development of innovative biodosimetry assays and devices that can identify biomarkers of injury and assess absorbed doses, particularly in the context of public health emergencies involving radiation exposure. The funding will facilitate early- to mid-stage research with a total budget of approximately $4 million, allowing for 6-8 awards of up to $350,000 each per year, over a project duration of up to five years. Interested applicants must submit their proposals by May 31, 2024, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-003-Full-Announcement.html
    RFA-AI-24-003.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity directed at developing novel biodosimetry assays and devices for radiation exposure assessment. This initiative, titled "Novel Approaches for Radiation Biodosimetry Assays and Devices Development," seeks to enhance medical preparedness against radiation injuries stemming from public health emergencies. The funding will support early- to mid-stage research to identify biomarkers indicating injury and create fast, reliable techniques for assessing absorbed doses and predicting health outcomes. The goal is to develop methods adequate for immediate field use in radiation incidents, particularly focused on distinguishing between exposed individuals and the "worried well." Key application details include an anticipated budget of $4 million for 6-8 awards, with each requesting no more than $350,000 in direct costs annually, and a project duration of up to five years. Applicants are encouraged to submit proposals addressing specific research gaps and to provide milestones for progress assessment. In summary, this funding opportunity aims to advance understanding and mitigation of radiation injuries through biomarker research, thereby enhancing the country’s preparedness for radiological emergencies.
    Similar Opportunities
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)" aimed at advancing research in cancer treatment through innovative synthetic vulnerabilities linked to radiation therapy. This initiative seeks R01 research projects that explore actionable vulnerabilities in tumors that can be paired with radiation responses, with the goal of developing effective anticancer strategies and integrating them into precision medicine. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and governmental organizations, with applications due by 5 PM local time on September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.
    Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trials Not Allowed)," aimed at supporting innovative research during critical events that require rapid data collection on human health impacts. This initiative seeks to understand the consequences of natural and human-made disasters and significant policy changes, emphasizing the need for expedited research processes that allow for funding decisions within 4-6 months of application submission. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and tribal governments, with a total funding amount of $800,000 available to support 4-5 grants. Interested parties can find more information and apply by visiting the NIH grants website, with the application deadline set for December 1, 2025.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects that focus on the development and validation of innovative technologies to enhance the quality and handling of cancer-relevant biospecimens, addressing significant gaps in cancer research methodologies. The initiative is part of the National Cancer Institute's (NCI) broader Innovative Molecular Analysis Technologies (IMAT) Program, which seeks to improve cancer biology research, early detection, clinical diagnosis, and treatment, while also tackling health disparities. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with a submission deadline of October 3, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html.
    Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants," aimed at fostering community-engaged research to identify and mitigate health risks associated with environmental exposures. This initiative encourages multidisciplinary projects that actively involve community members in defining research questions and methodologies, with the goal of developing actionable public health plans based on research findings. The program is particularly focused on addressing health disparities and promoting environmental health justice, with a maximum funding amount of $500,000 available for direct costs over a period of up to five years. Interested applicants can find more information and apply by visiting the provided link or contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by September 7, 2025.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding initiative aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance the quality, handling, and preservation of cancer-related biospecimens, addressing issues such as pre-analytical degradation. The initiative is part of the broader Innovative Molecular Analysis Technologies (IMAT) Program and seeks to advance cancer research, early detection, and treatment while addressing health disparities. Eligible applicants include a diverse range of institutions and organizations, with a maximum funding amount of $150,000 per year for up to three years. The application deadline is October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities" (FON: PAR-24-109), aimed at supporting collaborative research into the impacts of disasters on healthcare systems serving vulnerable populations in the U.S. and its territories. The initiative focuses on understanding the long-term effects, defined as one year or more post-disaster, on access, delivery, and quality of healthcare services, with an emphasis on fostering resilience and mitigating disparities exacerbated by such events. Eligible applicants include a wide range of institutions, including educational organizations, nonprofits, and government entities, with a funding ceiling of $500,000. The application period opens on May 5, 2024, and closes on June 5, 2024, with further inquiries directed to NIH Grants Information at grantsinfo@nih.gov.